Changes in antibiotic usage and susceptibility in nosocomial Enterobacteriaceae and Pseudomonas isolates following the introduction of ertapenem to hospital formulary. Epidemiology and Infection 140(1): 115-125, 2012
A prospective multicenter evaluation of the impact of formulary conversion from ceftazidime to cefepime on the in vitro susceptibility of Pseudomonas aeruginosa The cefepime enterobacteriaceae resistance impact study. Abstracts of the General Meeting of the American Society for Microbiology 101: 21, 2001
Changing trend of microbiologic profile and antibiotic susceptibility of the microorganisms isolated in the neonatal nosocomial sepsis: a 14 years analysis. Journal of Maternal-Fetal and Neonatal Medicine 2019: 1-8, 2019
Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease 89(4): 328-333, 2017
Reduced Susceptibility to Cefepime in Clinical Isolates of Enterobacteriaceae Producing OXA-1 Beta-Lactamase. Microbial Drug Resistance 22(2): 141-146, 2016
Evaluation of in vitro activities of cefepime and other beta-lactams against nosocomial Enterobacteriaceae with respect to their beta-lactamase patterns in 8 Russian hospitals. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 196, 1998
The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey. International Journal of Medical Sciences 8(4): 339-344, 2011
Antibiotic resistance patterns in nosocomial gram-negative bacterial infections in units with heavy antibiotic usage. Journal of Tropical Pediatrics 50(1): 26-31, 2004
Susceptibility of bacterial isolates from nosocomial infections to cefepime and 9 other antibiotics A multicentre study in Poland. Journal of Hospital Infection 40(SUPPL A): P417, Sept, 1998
Antimicrobial susceptibility and pharmacodynamic comparison of piperacillin-tazobactam and cefepime against enterobacteriaceae with extended-spectrum beta-lactamase. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 197, 2001
In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. Pathogens 4(3): 620-625, 2015
Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia. Open Forum Infectious Diseases 3(3): Ofw132, 2016
In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrobial Agents and ChemoTherapy 59(5): 2688-2694, 2016
Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clinical Infectious Diseases 56(4): 488-495, 2013
Bacteria susceptibility to cefepime in a hospital before its introduction. Journal of Hospital Infection 40(SUPPL A): P413, Sept, 1998